A Retrospective Comparison of 3-Factor Prothrombin Complex Concentrate Products for Warfarin Reversal
© The Author(s) 2020..
BACKGROUND AND PURPOSE: Current guidelines suggest that 3-factor prothrombin complex concentrate is a possible alternative to 4-factor products for the emergent reversal of bleeding secondary to warfarin. While multiple observational studies have evaluated various forms of 3-factor prothrombin complex concentrate individually, no study has compared the efficacy of the 2 products. The purpose of this study is to compare the efficacy and safety of Bebulin™ and Profilnine™ for the emergent reversal of warfarin-associated major bleeding.
METHODS: We conducted a retrospective cohort study of patients receiving both Bebulin™ and Profilnine™ at an urban, academic medical center with comprehensive stroke center designation and a neurosurgical center of excellence. All patients were treated at a single center that utilized a fixed, weight-based dosing protocol. The primary outcome was the percentage of patients in each group achieving a goal international normalization ratio of 1.4 or less.
RESULTS: There was a significant difference in goal international normalization ratio achieved favoring Bebulin™ (85.5% vs 27.3%; P < .001) over Profilnine™. Median dose per kilogram of actual body weight was the same between the groups. When we assessed results by baseline™ international normalization ratio subgroup, more patients in the Bebulin™ group achieved goal when baseline values were 6 or less. No thrombotic events were documented in either group.
CONCLUSIONS: We found that patients treated with Bebulin™ experienced significantly higher rates of successful international normalization ratio reversal when compared to those who received Profilnine™. Further research is needed to determine the comparative efficacy between the 2 agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The Neurohospitalist - 10(2020), 3 vom: 10. Juli, Seite 201-207 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jones, G Morgan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulation therapy |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/1941874420905755 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311287247 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311287247 | ||
| 003 | DE-627 | ||
| 005 | 20231225141930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1941874420905755 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311287247 | ||
| 035 | |a (NLM)32549944 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jones, G Morgan |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Retrospective Comparison of 3-Factor Prothrombin Complex Concentrate Products for Warfarin Reversal |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. | ||
| 520 | |a BACKGROUND AND PURPOSE: Current guidelines suggest that 3-factor prothrombin complex concentrate is a possible alternative to 4-factor products for the emergent reversal of bleeding secondary to warfarin. While multiple observational studies have evaluated various forms of 3-factor prothrombin complex concentrate individually, no study has compared the efficacy of the 2 products. The purpose of this study is to compare the efficacy and safety of Bebulin™ and Profilnine™ for the emergent reversal of warfarin-associated major bleeding | ||
| 520 | |a METHODS: We conducted a retrospective cohort study of patients receiving both Bebulin™ and Profilnine™ at an urban, academic medical center with comprehensive stroke center designation and a neurosurgical center of excellence. All patients were treated at a single center that utilized a fixed, weight-based dosing protocol. The primary outcome was the percentage of patients in each group achieving a goal international normalization ratio of 1.4 or less | ||
| 520 | |a RESULTS: There was a significant difference in goal international normalization ratio achieved favoring Bebulin™ (85.5% vs 27.3%; P < .001) over Profilnine™. Median dose per kilogram of actual body weight was the same between the groups. When we assessed results by baseline™ international normalization ratio subgroup, more patients in the Bebulin™ group achieved goal when baseline values were 6 or less. No thrombotic events were documented in either group | ||
| 520 | |a CONCLUSIONS: We found that patients treated with Bebulin™ experienced significantly higher rates of successful international normalization ratio reversal when compared to those who received Profilnine™. Further research is needed to determine the comparative efficacy between the 2 agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anticoagulation therapy | |
| 650 | 4 | |a hematology | |
| 650 | 4 | |a hemorrhagic disorders | |
| 650 | 4 | |a prothrombin | |
| 700 | 1 | |a Cave, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Ryan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Neurohospitalist |d 2011 |g 10(2020), 3 vom: 10. Juli, Seite 201-207 |w (DE-627)NLM229945279 |x 1941-8744 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:3 |g day:10 |g month:07 |g pages:201-207 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1941874420905755 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 3 |b 10 |c 07 |h 201-207 | ||